ADMA Biologics (ADMA)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.68 (+3.55%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of ADMA Biologics (ADMA)
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Key Insights

Critical company metrics and information
  • Share Price

    $19.82
  • Market Cap

    $4.69 Billion
  • Total Outstanding Shares

    236.39 Million Shares
  • Total Employees

    624
  • Dividend

    No dividend
  • IPO Date

    October 17, 2013
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Homepage

    https://www.admabiologics.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities, Continuing$86.05 Million
Net Cash Flow, Continuing$12.55 Million
Net Cash Flow From Financing Activities$-66.27 Million
Net Cash Flow$12.55 Million
Net Cash Flow From Investing Activities, Continuing$-7.23 Million
Net Cash Flow From Financing Activities, Continuing$-66.27 Million
Net Cash Flow From Investing Activities$-7.23 Million
Net Cash Flow From Operating Activities$86.05 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Operating Income/Loss$114.89 Million
Diluted Earnings Per Share$0.27
Preferred Stock Dividends And Other Adjustments$0.00
Benefits Costs and Expenses$23.00 Million
Costs And Expenses$259.58 Million
Selling, General, and Administrative Expenses$66.34 Million
Depreciation and Amortization$8.21 Million
Basic Average Shares$232.63 Million
Operating Expenses$72.41 Million
Nonoperating Income/Loss$-41.54 Million
Net Income/Loss Attributable To Parent$68.13 Million
Basic Earnings Per Share$0.29
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Research and Development$1.87 Million
Income/Loss From Continuing Operations After Tax$68.13 Million
Income/Loss From Continuing Operations Before Tax$359.81 Million
Revenues$382.81 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Cost Of Revenue$195.50 Million
Gross Profit$187.31 Million
Net Income/Loss$68.13 Million
Income Tax Expense/Benefit$5.22 Million
Diluted Average Shares$242.44 Million
Net Income/Loss Available To Common Stockholders, Basic$68.13 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Noncurrent Assets$72.42 Million
Accounts Payable$16.02 Million
Equity$231.89 Million
Other Non-current Assets$18.25 Million
Current Liabilities$44.89 Million
Noncurrent Liabilities$113.84 Million
Other Current Liabilities$28.87 Million
Equity Attributable To Parent$231.89 Million
Other Current Assets$146.39 Million
Inventory$171.80 Million
Assets$390.62 Million
Equity Attributable To Noncontrolling Interest$0.00
Current Assets$318.19 Million
Intangible Assets$485000.00
Liabilities$158.73 Million
Liabilities And Equity$390.62 Million
Fixed Assets$53.69 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Related Companies

View additional S&P 500 companies similar to ADMA Biologics (ADMA)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.